Trials / Active Not Recruiting
Active Not RecruitingNCT03261102
TDM Guided Early Optimization of ADAL in Crohn's Disease
Therapeutic Drug Monitoring Guided Early Optimization of Adalimumab in Crohn's Disease; A Randomized Open Label Study
- Status
- Active Not Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 200 (estimated)
- Sponsor
- waqqas.afif · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To investigate the influence of early therapeutic drug monitoring and dose optimization on disease outcome in Crohn's patients treated with Adalimumab.
Detailed description
This is an investigator initiated randomized open label study. This study is designed to compare whether increasing the dose of adalimumab based on the level the drug in the blood to a target level early in the treatment course would lead to better outcomes for patients as compared to the standard doses.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Adalimumab |
Timeline
- Start date
- 2017-01-17
- Primary completion
- 2025-01-15
- Completion
- 2025-06-01
- First posted
- 2017-08-24
- Last updated
- 2025-05-25
Locations
6 sites across 1 country: Canada
Source: ClinicalTrials.gov record NCT03261102. Inclusion in this directory is not an endorsement.